Genmab posts 22% nine‑month revenue growth and maintains full‑year guidance
+2 new sources since this summary was written
Genmab reported revenue of $3.238 billion for the first nine months of 2026, up 22% year over year, driven by higher royalties and Epkinly sales. Operating expenses rose 35% to $2.018 billion, pushing operating profit down to $986 million, while adjusted operating profit increased to $1.11 billion. The company announced European and Japanese approvals for epcoritamab and launched two Phase 3 petosemtamab trials, and it kept its full‑year guidance unchanged.
Why it matters
The maintained guidance suggests the company expects its late‑stage pipeline to sustain growth, which may support the current valuation. Investors should note the dip in operating profit due to higher expenses and integration charges, offset by stronger adjusted profit and new regulatory approvals.
Key facts
- 1Revenue for the first nine months was $3.238 billion, a 22% increase year over year. tipranks.com
- 2Operating expenses increased 35% to $2.018 billion. tipranks.com
- 3Operating profit fell to $986 million. investing.com
- 4Adjusted operating profit rose to $1.11 billion. investing.com
- 5Epcoritamab received approvals in Europe and Japan for relapsed or refractory follicular lymphoma. investing.com
- 6Genmab started two Phase 3 petosemtamab trials in colorectal cancer. tipranks.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.